Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss ... stocks to buy right now. See the 10 stocks » On Friday, however, Novo Nordisk announced top-line results ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Novo’s booming semaglutide franchise for ... During the first cycle, the 10 selected drugs ended up with 38% to 79% discounts off of their list prices. The biopharma industry has been objecting ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands ...

Most Wall Street professionals obsess over short-term returns. However, patient individual investors who buy and hold leading stocks on the cusp of new growth trends could strike it rich.

CMS included 10 drugs on its 2026 list and added another 15 (Ozempic, Wegovy, and Rybelsus are counted as one drug) for 2027. 2026 is the first year Medicare could select Novo Nordisk's ...